as 03-28-2025 3:30pm EST
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Founded: | 1996 | Country: | United States |
Employees: | N/A | City: | RANCHO CUCAMONGA |
Market Cap: | 1.3B | IPO Year: | 2014 |
Target Price: | $43.50 | AVG Volume (30 days): | 628.2K |
Analyst Decision: | Hold | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 3.06 | EPS Growth: | 17.69 |
52 Week Low/High: | $25.89 - $53.96 | Next Earning Date: | 05-07-2025 |
Revenue: | $731,967,000 | Revenue Growth: | 13.59% |
Revenue Growth (this year): | 2.6% | Revenue Growth (next year): | 9.42% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Petersen Floyd F. | AMPH | Director | Mar 6 '25 | Sell | $27.99 | 1,000 | $27,986.30 | 74,409 | |
PETERS WILLIAM J | AMPH | CFO, EVP & TREASURER | Mar 4 '25 | Sell | $27.54 | 4,231 | $116,515.39 | 97,363 |
AMPH Breaking Stock News: Dive into AMPH Ticker-Specific Updates for Smart Investing
ACCESS Newswire
3 days ago
Argus Research
5 days ago
StockStory
18 days ago
ACCESS Newswire
a month ago
StockStory
a month ago
Argus Research
a month ago
Simply Wall St.
a month ago
Insider Monkey
a month ago
The information presented on this page, "AMPH Amphastar Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.